MAGNUS HEALTH, LLC – Trademark Portfolio

Entity Type: 16

MAGNUS HEALTH, LLC holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include PNCEUTICA. The owner is based in RALEIGH, NC.

323 WEST MARTIN STREET

RALEIGH, NC 27601

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

PNCEUTICA
PNCEUTICA
Registered 2022
CAREFLOW
CAREFLOW
Cancelled 2009

Trademark Classifications

MAGNUS HEALTH, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does MAGNUS HEALTH, LLC have?

MAGNUS HEALTH, LLC has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 cancelled.

What trademark classes does MAGNUS HEALTH, LLC file in?

MAGNUS HEALTH, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.

What are MAGNUS HEALTH, LLC's most well-known trademarks?

MAGNUS HEALTH, LLC's registered trademark portfolio includes well-known marks such as PNCEUTICA. These are among 1 currently registered trademark in the portfolio.

What is MAGNUS HEALTH, LLC's trademark registration success rate?

MAGNUS HEALTH, LLC has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.